Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver

Molecular Pharmacology

Volumn 67, Issue 5, 2005, Pages 1765-1771

  Merino, Gracia ^a   Van Herwaarden, Antonius E ^a   Wagenaar, Els ^a   Jonker, Johan W ^a   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLAMIDAZO[4,5 B]PYRIDINE; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; BREAST CANCER RESISTANCE PROTEIN 1; CARCINOGEN; CIMETIDINE; NITROFURANTOIN; PYRIDINE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; BREAST CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; KIDNEY; KNOCKOUT MOUSE; LIVER METABOLISM; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SMALL INTESTINE; WESTERN BLOTTING;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIVER; MALE; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; NITROFURANTOIN; SEX CHARACTERISTICS;

EID: 17844372454     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.105.011080     Document Type: Article

References (35)

1. Allen JD and Schinkel AH (2002) Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein. Mol Cancer Ther 1:427-434.
2. Beierle I, Meibohm B, and Derendorf H (1989) Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 37:529-547.
3. Burger H, Van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, and Nooter K (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)ABCG2 drug pump. Blood 104:2940-2942.
4. Cisternino S, Mercier G, Bourasset F, Roux F, and Scherrmann JM (2004) Expression, upregulation and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64:3296-3301.
5. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, and Rubens RD (1995) Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36:473-476.
6. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
7. Fahrig L, Brasch H, and Iven H (1989) Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX. Cancer Chemother Pharmacol 23:156-160.
8. Farrier DS (1997) PK Solutions: a non compartmental pharmacokinetic data analysis program. Summit Research Services, Ashland, OH.
9. Gallo JM, Laub PB, Rowinsky EK, Grochow LB, and Baker SD (2000) Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 18:2459-2467.
10. Godfrey C, Sweeney K, Miller K, Hamilton R, and Kremer J (1998) The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 46:369-376.
11. Imai Y, Ishikawa E, Asada S, and Sugimoto Y (2005) Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 65:596-604.
12. Jaffe CA, Turgeon DK, Lown K, Demott-Friberg R, and Watkins PB (2002) Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. Am J Physiol 283:1008-1015.
13. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 26:15649-15654.
14. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, and Schinkel AH (2005) The breast cancer resistance protein (BCRP/ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127-129.
15. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JHM, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
16. Jonker JW, Wagenaar E, Mol CAAM, Buitelaar M, Koepsell H, Smit JW, and Schinkel AH (2001) Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the Organic Cation Transporter 1 (Oct1[Slc22a1]) gene. Mol Cell Biol 21:5471-5477.
17. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, et al. (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33:94-101.
18. Loos WJ, Gelderblom HJ, Verweij J, Brouwer E, de Jonge MJA, and Sparreboom A (2000) Gender-dependent pharmacokinetics of topotecan in adult patients. Anticancer Drugs 11:673-680.
19. Loos WJ, Gelderblom HJ, Verweij J, van Boven-van Zomeren DM, Nooter K, Stoter G, and Sparreboom A (2003) Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis. Anticancer Drugs 14:227-232.
20. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van de Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 15:3458-3464.
21. Meibohm B, Beierle I, and Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41:329-342.
22. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, and Schinkel AH (2005) The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 67:1758-1764.
23. Mizuarai S, Aozasa N, and Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 109:238-246.
24. Morris ME, Lee HJ, and Predko LM (2003) Gender differences in the membrane transport of endogenous and exogenous compounds. Pharmacol Rev 55:229-240.
25. +/peptide cotransporter in rat digestive tract. Biochem Biophys Res Commun 220:848-852.
26. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, and Schinkel AH (2005) Human breast cancer resistance protein (BCRP/ABCG2): interactions with steroid drugs, hormones, the dietary carcinogen PhIP and transport of cimetidine. J Pharmacol Exp Ther 312:144-152.
27. Schuetz EG, Furuya KN, and Schuetz JD (1995) Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275:1011-1018.
28. Schwartz JB (2003) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42:107-121.
29. Shapiro BH, Agrawal AK, and Pampori NA (1995) Gender differences in drug metabolism regulated by growth hormone. Int J Biochem Cell Biol 27:9-20.
30. Simon FR, Fortune J, Iwahashi M, Bowman S, Wolkoff A, and Sutherland E (1999) Characterization of the mechanisms involved in the gender differences in hepatic taurocholate uptake. Am J Physiol 276:G556-G565.
31. Sparreboom A, Gelderbloom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij, and McLeod HL (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C→A genotype. Clin Pharmacol Ther 76:38-44.
32. Tanaka Y, Slitt AL, Leazer TM, Maher JM, and Klaassen CD (2004) Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun 31:181-187.
33. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, and Schinkel AH (2003) The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine. Cancer Res 63:6447-6452.
34. Wade JR, Kelman AW, Kerr DJ, Robert J, and Whiting B (1992) Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol 29:391-395.
35. Wall AM, Gajjar A, Link A, Mahmoud H, Pui CH, and Relling MV (2000) Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia 14:221-225.